USA flag logo/image

An Official Website of the United States Government

A TWO-SITE IMMUNOASSAY WILL BE DEVELOPED AGAINST APOLIPO- PROTEIN A-I (APOA-I),…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
5000
Program Year/Program:
1986 / SBIR
Agency Tracking Number:
5000
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Solomon Park Research Labs
12815 Ne 124th Street Kirkland, WA 98304
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1986
Title: A TWO-SITE IMMUNOASSAY WILL BE DEVELOPED AGAINST APOLIPO- PROTEIN A-I (APOA-I), THE MAJOR APOPROTEIN OF HIGH-DENSITY LIPOPROTEIN (HDL).
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

A TWO-SITE IMMUNOASSAY WILL BE DEVELOPED AGAINST APOLIPO- PROTEIN A-I (APOA-I), THE MAJOR APOPROTEIN OF HIGH-DENSITY LIPOPROTEIN (HDL). LOW LEVELS OF APOA-I HAVE BEEN POSITIVELY CORRELATED WITH CORONARY ARTERY DISEASE (CAD). TO ENSURE ADEQUATE QUANTIFICATION, CYANOGEN BROMIDE (CNBR) FRAGMENTS OF APOA-I WILL BE USED TO GENERATE MONOCLONAL ANTIBODIES (MABS), WHICH WILL BE SELECTED TO RECOGNIZE SEPARATE EPITOPES ON THE SOLUBLE PROTEIN IN UNTREATED PLASMA. THE ASSAY SYSTEM USED WILL BE THE ENZYME-LINKED IMMUNOSORBANT ASSAY (ELISA). QUANTITATIVE RESULTS FROM THE ELISA WILL BE CORRELATED WITH OTHER IMMUNOASSAYS AND WITH ASSAYS BASED ON DIRECT MEASUREMENT OF PROTEIN MASS. THE ULTIMATE GOAL WILL BE TO DEVELOP ELISA KITS FOR RESEARCH ANDCLINICAL MEASUREMENT OF THIS IMPORTANT CAD RISK FACTOR.

Principal Investigator:

Patric a clapshaw
PRINCIPAL INVESTIGATOR
2068217005

Business Contact:

Small Business Information at Submission:

Solomon Park Research Labs
12815 Ne 124th Street Kirkland, WA 98304

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No